Novartis
CHF 118.06Change from previous close: −1.58%Absolute change: −CHF 1.90
Valuation
Data as of October 1, 2026
Valuation multiples
- Market cap
- CHF 224.4B
- Enterprise value
- CHF 266.2B
- P/E (trailing 12 months)
- 21.4
- Forward P/E
- 14.4
- PEG
- 3.41
- Price/book
- 6.55
- Price/sales
- 3.96
- EV/EBITDA
- 11.5
- EV/revenue
- 4.70
Profitability and growth
- Gross margin
- 75.0%
- Operating margin
- 34.6%
- Net margin
- 22.5%
- ROE
- 30.4%
- ROA
- 10.3%
- Revenue growth (year over year)
- 0.8%
- Earnings growth (year over year)
- -17.0%
Financial health
- Total cash
- CHF 7.62B
- Total debt
- CHF 49.01B
- Debt/equity
- 1.17
- Current ratio
- 0.86
- Quick ratio
- 0.55
Dividends
- Annual dividend per share
- CHF 3.70
- Dividend yield
- 3.1%
- Payout ratio
- 69.9%
- Ex-dividend date
- March 10, 2026
Analysts and estimates
- Average price target
- CHF 126.24
- Median price target
- CHF 126.58
- High price target
- CHF 151.25
- Low price target
- CHF 100.51
- Number of analysts
- 22
- Consensus
- Hold
- Forward EPS
- CHF 8.22
- EPS estimate, current year
- CHF 8.84
Shares and trading
- Beta
- 0.49
- Average volume
- 2.72M
- Shares outstanding
- 1.9B
- Float
- 1.86B
- Institutional ownership
- 46.0%
- Insider ownership
- 2.1%